Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 15 versus DYANAVEL XR 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 15 versus DYANAVEL XR 5.
ADDERALL 15 vs DYANAVEL XR 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
CNS stimulant; blocks reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their synaptic concentrations.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
20 mg orally once daily in the morning; may increase by 10 mg weekly based on response; maximum 60 mg/day.
None Documented
None Documented
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Terminal elimination half-life for d-amphetamine is 10-13 hours; for l-amphetamine, 13-16 hours. Clinical context: Twice-daily dosing may be required for sustained effect.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Renal: ~90% as unchanged amphetamine and metabolites. Fecal: minimal (<5%).
Category C
Category C
CNS Stimulant
CNS Stimulant